1 Underrated Stock That Could Soar by 58%, According to Wall Street

Core Viewpoint - CRISPR Therapeutics is experiencing a pullback in its stock price despite a strong start to the year, with shares down 23% over the past month, but Wall Street remains optimistic with an average price target of $82.41, indicating a potential upside of nearly 58% from current levels [1]. Group 1: Product Development and Sales - CRISPR Therapeutics achieved a significant milestone with the approval of Casgevy, the first CRISPR-based gene-editing medicine for sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals [3]. - The launch of Casgevy has been disappointing, with only 165 patient cell collections completed as of the third quarter, resulting in revenue of $889,000, a modest increase from $602,000 in the same quarter last year [4]. - Despite the slow start, there is optimism that Casgevy will gain traction next year, targeting approximately 60,000 patients, which could lead to improved sales and financial performance for CRISPR Therapeutics [5]. Group 2: Clinical Development Pipeline - Monitoring the clinical development of CRISPR Therapeutics is crucial, as the company has several promising candidates in early-stage studies, including CTX310, aimed at lowering LDL cholesterol and triglycerides, which are linked to cardiovascular conditions [6]. - The company’s sole approved product currently does not generate significant sales, but there are pipeline candidates that could progress in the coming year, presenting substantial upside potential despite inherent risks [7].